- TLDR Biotech
- Archive
- Page 0
The Latest Biotech & Pharma Updates
Biotech & Pharma Updates | April 15 - 16, 2025
Ayrmid misses upped bluebird bio offer deadline, Glycomine raises $115M Series C to develop treatment for rare disease PMM2-congenital disorder of glycosylation, Dutch cabinet envisions Netherlands as global biotech leader by 2040 - investing €1.3 billion ($1.48 billion) to accelerate innovations to market, EU and US pharma companies demand EC support in facing US tariffs, CDC struggles to respond to Texas measles outbreak + 31 more stories
Biotech & Pharma Updates | April 14 - 15, 2025
Pharma’s bellweather J&J posts upbeat Q1 results and maintains guidance, though marco headwinds persist, eGenesis and OrganOx receive FDA IND clearance to test gene-edited pig livers in liver failure, Trump orders Congress to remove IRA's "pill penalty" in effort to lower drug prices, Sanofi's amlitelimab (anti-OX40) misses primary endpoint in Ph2 asthma trial + 34 more stories
Biotech & Pharma Updates | April 13 - 14, 2025
Pfizer discontinues oral obesity drug program after “review[ing]...the totality of information“, Roche's Columvi lands EC approval in lymphoma, AbbVie and Sandoz settle patent lawsuit over Rinvoq (targeting JAK), Third Harmonic Bio plans to dissolve by Q3 2025, US Commerce Secretary Lutnick confirms pharmaceutical tariffs are coming + 26 more stories
Biotech & Pharma Updates | April 10 - 13, 2025
Biotech industry alarmed that FDA's staff reductions and hiring freeze will threaten US leadership in drug development leadership and cause massive regulatory delays, Bristol Myers Squibb's Opdivo plus Yervoy combo lands FDA approval for first-line unresectable or metastatic hepatocellular carcinoma, Kyowa Kirin completes $118M biologics plant in Japan, Vanda Pharmaceuticals sues FDA for right to promote Hetlioz off-label for jet lag disorder after FDA rejected its application for expanded use + 20 more stories
Biotech & Pharma Updates | April 9 - 10, 2025
Novartis announces $23B investment to expand US manufacturing and R&D facilities, Belief BioMed and Takeda's hemophilia B gene therapy lands Chinese NMPA approval, Imbria Pharmaceuticals $57.5M Series B to developer pFOX inhibitor for non-obstructive hypertrophic cardiomyopathy + cardiometabolic diseases, FDA will phase out required animal testing for drugs + 36 more stories
Biotech & Pharma Updates | April 8 - 9, 2025
A temporary tariff reprieve (key word "temporary"), Solu Therapeutics $41M Series A for next-gen leukemia treatment, BMS wins class action dismissal regarding Pomalyst generic competition, Vincerx Pharma to winding down after third failed merger attempt, President Trump planning major tariffs on pharmaceuticals + 26 more stories
Biotech & Pharma Updates | April 7 - 8, 2025
EU could be facing a $100B investment drain amidst US tariffs, Merida Biosciences $121M launch to develop Fc-based therapies targeting autoimmune + allergic diseases, BMS' Opdivo+Yervoy combo FDA approval for first-line metastatic colorectal cancer, UK investing $764M with Wellcome Trust in health data repository, Tango Therapeutics cuts 20% of staff + 26 more stories
Biotech & Pharma Updates | April 6 - 7, 2025
BioMed X launches XBridge Program to connect threatened NIH grants with pharmaceutical industry funding partners, DualityBio files for $200M Hong Kong IPO amid market uncertainty, Centessa Pharmaceuticals' orexin receptor agonist delivers promising Ph1 data in narcolepsy treatment, GSK & ABL Bio partner to develop neurodegenerative disease treatments using ABL's blood-brain barrier shuttle platform, AmplifyBio shuts down after failed attempts to secure funding amid declining market for early-stage cell and gene therapies + 28 more stories
Biotech & Pharma Updates | April 3 - 6, 2025
Sanofi and Cathay Capital launch $275.1M innovation fund targeting clinical-stage drug pipeline in China, RJK Jr. endorses MMR vaccine against measles, Sarepta's Elevidys clinical trials recommended to continue by data monitoring committee, RayThera $110M Series A to advancing small molecule immunology drug candidates, RFK Jr. admits 20% of 10k+ HHS layoffs were mistakes (planning on rehiring) + 30 more stories
Biotech & Pharma Updates | April 2 - 3, 2025
Neurona Therapeutics' $102M fundraise for drug-resistant epilepsy cell therapy, Novartis' IgA nephropathy therapy Vanrafia lands FDA accelerated approval, Sangamo out-licenses novel AAV capsid to Eli Lilly for genomic medicine delivery across the blood-brain barrier, Boehringer Ingelheim invests $31M into new Swiss ADC facility, BeiGene discontinues anti-TIGIT antibody after Ph3 trial stumble in non-small cell lung cancer + 33 more stories
Biotech & Pharma Updates | April 1 - 2, 2025
Atsena Therapeutics $150M Series C for rare genetic eye disease gene therapy, Sanofi pays Nurix Therapeutics $15M upfront rights to "once-undruggable" transcription factor degrader, BioMarin's Palynziq enzymatic therapy delivers positive Ph3 data for adolescents with PKU, Edgewise Therapeutics' spooks investors with EDG-7500 Ph2 results in hypertrophic cardiomyopathy, researchers sue NIH and HHS leaders over $1.1 billion in unlawfully canceled research grants + 29 more stories
Biotech & Pharma Updates | March 31 - April 1, 2025
FDA layoffs spark concerns about US drug regulation, AIRNA $155M Series B for RNA editing therapies in rare genetic diseases, Eagle Pharmaceuticals sells Bendeka royalty rights, Eli Lilly's solbinsiran (targeting ANGPTL3) delivers positive Ph2 data in mixed dyslipidemia, Carisma Therapeutics begins company shutdown process + 30 more stories